Phase I and Pharmacokinetic Study of the Vascular‐disrupting Agent CKD‐516 (NOV120401) in Patients With Refractory Solid Tumors
Pharmacology Research and Perspectives - United Kingdom
doi 10.1002/prp2.568
Full Text
Open PDFAbstract
Available in full text
Date
March 12, 2020
Authors
Publisher
Wiley